OCTOBER 12, 2023 - OCTOBER 14, 2023

Back to Event Homepage

MEDS Summer Submissions are Now Closed

 

MEDS FALL SUBMISSION INSTRUCTIONS

 

SUBMISSION DEADLINE: August 30, 2023

 

NOTIFICATION DATE: September 8, 2023

 

We invite all registered meeting attendees to submit abstracts for posters of their latest research on the following topics:

 

  • Thyroid disorders
  • Pituitary and adrenal disorders
  • Polycystic ovary syndrome (PCOS)
  • Osteoporosis
  • Diabetes
  • Obesity management
  • Chronic kidney disease & diabetes
  • Nonalcoholic fatty liver disease (NAFLD)

 

All accepted abstracts will be displayed at the Metabolic and Endocrine Disease Summit Fall, October 12–14, 2023 to be held in, Lake Buena Vista, Florida.  

 

In addition, approved abstracts will also be submitted and indexed through our partner brand, Read by QxMD. Read by QxMD drives awareness, dissemination, and engagement with content via the Read by QxMD platform, as an educational tactic to drive CQI. The Read by QxMD platform works on iPhone, iPad, Android smartphones & tablets, and any web-enabled device (including desktops), and uses channels such as mobile, email, and push notification to connect with our global community of healthcare providers and researchers.

apple app store

If you are returning to complete or check the status of your submission, please sign-in using your email address and password.

 

Fee: No fee for non-industry-sponsored abstracts; $495 per abstract for industry-sponsored abstracts.
At least one (1) author must be registered for the in-person meeting to have their abstracts considered for oral presentation and/or poster display. All submissions accepted for oral presentation must also create a poster for display.

 

SUBMISSION DEADLINE:Encore posters are welcome!

 

Abstract Formatting and Content Guidelines
You must be registered for the meeting to have your abstract considered for a presentation.

  • Language: English 
  • Authors: full last name, first name, affiliations, degrees and contact information
  • Font: Arial
  • Maximum of 3000 characters, including spaces (not including the title, authors, or affiliations)
  • Maximum of 2 relevant tables or figures submitted as attachments (not embedded in the file): must be 600 dpi .jpg 
  • References must be included as parenthetical in-text citations - first author, et al, journal and year - (Cruz D, et al. Blood 2012)
  • Full contact information of corresponding author (Please ensure that your email address is accurate, as all correspondence will be sent via email) 
  • Abstract text should preferably be in a "structured abstract" form with sections marked Background, Objectives, Methods, Results, Disclosures, and Conclusions 
  • Abstracts containing non-generic drug names or personal patient information, or reporting studies with unidentified chemical compounds, drugs, or materials, will not be accepted.

 

If you have any questions, please contact Andi Koral at akoral@medscapelive.com.